Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Beta-catenin gene (CTNNB1) mutations have been described predominantly in intestinal-type gastric cancers and CTNNB1 gene amplification and overexpression have recently been described in a mixed-type gastric cancer.
|
15895459 |
2005 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A beta-catenin gene mutation was identified only in one intestinal-type gastric cancer exhibiting a massive overexpression of beta-catenin mRNA in the tumour.
|
11756228 |
2002 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A small portion of GCs expressed LGR5.Although LGR5 was associated with poor survival in GCs with nuclear β-catenin, LGR5 expression in GC cells had no effects on the growth and migration, requiring a further study exploring a biological role of LGR5 in GCs.
|
26386561 |
2016 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Adenomatous polyposis coli gene, beta-catenin, and E-cadherin expression in proximal and distal gastric cancers and precursor lesions: an immunohistochemical study using tissue microarrays.
|
12966349 |
2003 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Allograft inflammatory factor-1 is an independent prognostic indicator that regulates β-catenin in gastric cancer.
|
24337893 |
2014 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although, Siah1 could not increase degradation of the cytosolic β-catenin and its nuclear translocation, it enhanced degradation of the membrane-bound β-catenin in the infected GCCs.
|
28481365 |
2017 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Attenuation of beta-catenin by shRNA resulted in suppressed cell proliferation and apparent apoptosis, suggesting that beta-catenin may be a target for therapy of gastric cancer.
|
19958059 |
2009 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
AURKA induces EMT by regulating histone modification through Wnt/β-catenin and PI3K/Akt signaling pathway in gastric cancer.
|
27121204 |
2016 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
By the methods of frozen tissue array-based immunohistochemistry, Western blot analysis and RT-PCR, a paralleled study was conducted to check Wnt2 expression and beta-catenin intracellular distribution in two major subtypes of gastric cancers (intestinal gastric cancer, i-GC and diffuse gastric cancer, d-GC) and their premalignant (intestinal metaplasia, IM and chronic gastritis, CG) and noncancerous counterparts.
|
15896469 |
2005 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Calcyclin-binding protein/Siah-1-interacting protein (CacyBP/SIP), a target protein of S100, has been identified as a component of a novel ubiquitinylation complex leading to beta-catenin degradation, which was found to be related to the malignant phenotypes of gastric cancer.
|
17400182 |
2007 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chitinase 3-like 1-CD44 interaction promotes metastasis and epithelial-to-mesenchymal transition through β-catenin/Erk/Akt signaling in gastric cancer.
|
30165890 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Chi‑square tests suggested that STIM1 expression in GC tissues was significantly associated with E‑cadherin (P<0.001) and β‑catenin (P<0.001), whereas no association was observed between STIM1 and MMP‑9 expression (P>0.05).
|
28534934 |
2017 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
CLDN1 and β-catenin showed similar prognostic value in intestinal-type gastric cancers.
|
24535143 |
2014 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, knockdown of AGGF1 inhibits the invasion and migration of gastric cancer via epithelial-mesenchymal transition through Wnt/β-catenin pathway.
|
30858758 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, we found that miR-19/MEF2D/Wnt/β-catenin regulatory network contributes to the growth of gastric cancer, hinting a new promising target for gastric cancer treatment.
|
26762410 |
2016 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diallyl disulfide inhibits TGF‑β1‑induced upregulation of Rac1 and β‑catenin in epithelial‑mesenchymal transition and tumor growth of gastric cancer.
|
29620286 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
E-cadherin/beta-catenin proteins expression and histopathologic features were examined on gastric cancer/breast cancer tissues from the proband.
|
15135482 |
2004 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
ERα overexpression effectively inhibited cell growth and cancer progression by suppressing β-catenin in gastric cancer, identifying ERα as a promising target with therapeutic potential for development of new approaches to treat gastric cancer.
|
23843035 |
2013 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Examples of genes involved in pathogenesis of GC include p53, adenomatous polyposis coli (APC), beta-catenin, E-cadherin, transforming growth factor (TGF)-betaRII, and hMLH1.
|
14517582 |
2003 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression patterns of the tumor suppressor PDCD4 and correlation with β-catenin expression in gastric cancers.
|
21894439 |
2011 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Frequent loss of membranous E-cadherin in gastric cancers: A cross-talk with Wnt in determining the fate of beta-catenin.
|
16132582 |
2005 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Frizzled7 Promotes Epithelial-to-mesenchymal Transition and Stemness Via Activating Canonical Wnt/β-catenin Pathway in Gastric Cancer.
|
29559846 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
FRZB knockdown may upregulate the Wnt/β‑catenin pathway and promote aggressiveness in gastric cancer.
|
24676361 |
2014 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, knockdown of UBE2C using siRNA markedly reduced the level of phosphorylation AURKA (p‑AURKA) via Wnt/β‑catenin and PI3K/Akt signaling pathways suppressed the occurrence and development of gastric cancer.
|
28260026 |
2017 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the overexpression of Egr-1 upregulated β-catenin expression level, promoted cell proliferation, increased cell population in S-phase and enhanced gastric cancer cell migration and invasion in vitro.
|
22918686 |
2013 |